In a recent study published in the journal eClinicalMedicine, researchers investigated the association of metabolic syndrome (MetS) with pancreatic cancer.
Reviewed Blueprint Medicines Corporation today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok